Therapeutic Goods (Exempt Monographs) Amendment Determination 2022
I, Nick Henderson, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 25 March 2022
Nick Henderson
First Assistant Secretary
Medicines Regulation Division
Health Products Regulation Group
Department of Health
Contents
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments
Therapeutic Goods (Exempt Monographs) Determination 2021
Schedule 2—Repeals
Therapeutic Goods (Exempting monographs of pharmacopoeias) Determination No. 1 of 2011
This instrument is the Therapeutic Goods (Exempt Monographs) Amendment Determination 2022.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 31 March 2022. | 31 March 2022 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under section 3C of the Therapeutic Goods Act 1989.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Therapeutic Goods (Exempt Monographs) Determination 2021
1 Schedule 1 (at the end of the table)
Add:
antithrombin III human | United States Pharmacopeia-National Formulary | therapeutic goods | |
3 | factor IX complex | United States Pharmacopeia-National Formulary | therapeutic goods |
4 | pancreatin | United States Pharmacopeia-National Formulary | therapeutic goods |
5 | pancrelipase | United States Pharmacopeia-National Formulary | therapeutic goods |
6 | plasma protein fraction | United States Pharmacopeia-National Formulary | therapeutic goods |
Therapeutic Goods (Exempting monographs of pharmacopoeias) Determination No. 1 of 2011
1 The whole of the instrument
Repeal the instrument.